Torbay Hospital

Running trials

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Phase 3· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Source

• Recruiting

  Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Phase 3· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06497556· Phase 3· Source

• Recruiting

  Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

  NCT05655078· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Source

• Recruiting

  A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

  NCT06461208· Phase 3· Source

• Active, not recruiting

  First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

  NCT06398743· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Source

• Recruiting

  Met Non Small Cell Cancer Registry (MOMENT)

  NCT05376891· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

  NCT04712097· Phase 3· Source

• Active, not recruiting

  Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04546620· Phase 2· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· Source

• Active, not recruiting

  Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

  NCT04056247· Source

• Recruiting

  Renal Adjuvant MultiPle Arm Randomised Trial

  NCT03288532· Phase 3· Source

• Active, not recruiting

  UK Infinity, Post-Market Clinical Follow-up Study

  NCT03063593· Source

• Active, not recruiting

  CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

  NCT04116047· Phase 3· Source

• Active, not recruiting

  Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

  NCT00268476· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Childhood cancers2 recruiting
• Heart failure2 recruiting
• Diabetic eye disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Mesothelioma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  NCT06064877· Phase 3· Source

• Completed

  Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers

  NCT04750109· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· Source